Baradaran Hamid Reza, Dehghanbanadaki Hojat, Moradpour Farhad, Eshrati Babak, Moradi Ghobad, Azami Mobin, Haji Ghadery Abdolkarim, Mehrabi Nejad Mohammad-Mehdi, Moradi Yousef
Ageing Clinical & Experimental Research Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Expert Rev Vaccines. 2022 Oct;21(10):1455-1464. doi: 10.1080/14760584.2022.2102001. Epub 2022 Jul 22.
We systematically reviewed the literature to investigate the pooled effect of COVID-19 mRNA vaccination against SARS-CoV-2 infection and its clinical outcomes.
Scopus, Web of Science, PubMed (Medline), and Embase were searched on 9 September 2021. The odds ratio (OR) of COVID-19 infection and its clinical outcomes in fully/ partially vaccinated versus unvaccinated participants were calculated and pooled by using a random-effects model.
The pooled analysis showed that among health care workers and general population, vaccinated participants with one or two doses were less likely to infect with SARS-CoV-2 (OR = 0.16; 95%CI: 0.08-0.32; I = 79.86%; 95%CI I: 68.99-87.21%), to develop symptomatic COVID-19 infection (OR = 0.09; 95%CI: 0.03-0.32; I = 80.43%; 95%CI I: 70.83-89.33%), to admit to the hospital because of COVID-19 (OR = 0.13; 95%CI: 0.06-0.28; I = 86.19%; 95%CI I: 67.80-93.88%), and to die from COVID-19 (OR = 0.14; 95%CI: 0.06-0.35; I = 66.76%; 95%CI I: 54.00-76.99%) than unvaccinated participants.
COVID-19 mRNA vaccines, especially following administration of two doses, are extremely effective. It would be suggested further studies with large sample size and different ethnicities to be conducted among the general population to warrant these results.
我们系统回顾了文献，以研究新冠病毒mRNA疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染及其临床结局的综合影响。
于2021年9月9日检索了Scopus、科学网、PubMed（医学索引数据库）和Embase。计算并使用随机效应模型汇总了完全/部分接种疫苗与未接种疫苗参与者中新冠病毒感染及其临床结局的优势比（OR）。
汇总分析表明，在医护人员和普通人群中，接种一剂或两剂疫苗的参与者感染SARS-CoV-2的可能性较小（OR = 0.16；95%置信区间：0.08 - 0.32；I² = 79.86%；95%置信区间I²：68.99 - 87.21%），出现有症状的新冠病毒感染的可能性较小（OR = 0.09；95%置信区间：0.03 - 0.32；I² = 80.43%；95%置信区间I²：70.83 - 89.33%），因新冠病毒住院的可能性较小（OR = 0.13；95%置信区间：0.06 - 0.28；I² = 86.19%；95%置信区间I²：67.80 - 93.88%），死于新冠病毒的可能性较小（OR = 0.14；95%置信区间：0.06 - 0.35；I² = 66.76%；95%置信区间I²：54.00 - 76.99%），低于未接种疫苗的参与者。
新冠病毒mRNA疫苗，尤其是接种两剂后，极其有效。建议在普通人群中开展更大样本量和不同种族的进一步研究，以证实这些结果。
